There is an urgent need for imaging biomarkers to develop new therapies for progressive multiple sclerosis. Hardware upgrades can confound the outcomes of imaging in clinical trials of such therapies. We examine different analytic approaches to evaluating the impact of and correcting for the effects of hardware changes in a retrospective analysis of SPRINT-MS, a multi-center clinical trial. Brain parenchymal fraction (BPF), a measure of atrophy, and transverse diffusivity (TD), a measure of demyelination are examined.
This abstract and the presentation materials are available to members only; a login is required.